RAPT Therapeutics, Inc. Retained Earnings
RAPT Therapeutics, Inc. had Retained Earnings of -$666.93 million as of 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2025-11-06
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$666.93M.
- 2025-06-30: Retained Earnings (Accumulated Deficit) -$649.36M.
- 2025-03-31: Retained Earnings (Accumulated Deficit) -$631.71M.
- 2024-12-31: Retained Earnings (Accumulated Deficit) -$614.55M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2025-09-30 | -$666.93M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$649.36M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$631.71M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$614.55M 10-Q · filed 2025-11-06 |
| 2024-09-30 | -$561.30M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$542.87M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$515.20M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$484.68M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$453.81M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$422.44M 10-Q · filed 2023-08-11 |
| 2023-03-31 | -$397.15M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$367.88M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$344.93M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$323.70M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$304.51M 10-Q · filed 2022-05-11 |
| 2021-12-31 | -$284.05M 10-K · filed 2023-03-14 |
| 2021-09-30 | -$266.12M 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$247.47M 10-Q · filed 2021-08-11 |
| 2021-03-31 | -$231.36M 10-Q · filed 2021-05-11 |
| 2020-12-31 | -$214.84M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$202.11M 10-Q · filed 2020-11-16 |
| 2020-06-30 | -$187.48M 10-Q · filed 2020-08-13 |
| 2020-03-31 | -$175.09M 10-Q · filed 2020-05-14 |
| 2019-12-31 | -$161.95M 10-K · filed 2021-03-11 |
| 2019-09-30 | -$148.73M 10-Q · filed 2019-12-11 |
| 2018-12-31 | -$118.95M 10-K · filed 2020-03-30 |